Daré Bioscience’s (DARE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a $6.00 target price on the biotechnology company’s stock.

Several other equities analysts have also commented on the stock. Brookline Capital Management lowered shares of Daré Bioscience from a buy rating to a hold rating in a research report on Wednesday, April 17th. Dawson James lowered Daré Bioscience from a buy rating to a neutral rating in a research report on Tuesday, January 30th.

Daré Bioscience Stock Performance

Shares of Daré Bioscience stock opened at $0.31 on Wednesday. The firm has a market cap of $31.30 million, a PE ratio of -0.92 and a beta of 1.31. The stock has a 50 day moving average of $0.44 and a 200 day moving average of $0.39. Daré Bioscience has a 12 month low of $0.27 and a 12 month high of $1.06.

Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06. The firm had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $2.17 million. As a group, equities research analysts forecast that Daré Bioscience will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Daré Bioscience stock. Armistice Capital LLC bought a new position in Daré Bioscience, Inc. (NASDAQ:DARE) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned about 7.37% of Daré Bioscience at the end of the most recent quarter. Institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.